The U.S. and China agree to $60 billion in tariff cuts on products like dolls and fireworks. Rare earths remain a sticking point.
THE SO WHAT
Tariff relief on low-tech goods while rare earths stay contentious underlines that the real leverage is still in upstream inputs to chips, batteries, and motors. If your roadmap depends on magnets, batteries, or advanced materials, treat China supply as structurally fragile regardless of headline tariff de-escalations.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechEurope and UAE plan $1 billion orbital data center with 50 connected "computers" and a central "LLM store" that allows users to select what open source model to use on data collected by satellite sensors
An in-orbit “LLM store” tied to 50 AI-equipped EO satellites is a bet that the bottleneck in space data is now on-orbit processing and model choice, not downlink. If you depend on geospatial data, start mapping which workloads could move from batch ground analysis to near-real-time orbital inference and what that does to your latency and bandwidth assumptions.
Deep & Emerging TechAI is supercharging hacking, and your local hospitals and banks aren’t ready
If AI is lowering the skill floor for attackers while hospitals and local banks still run fragile, underfunded IT, the asymmetry is getting worse, not better. Boards in regulated sectors should treat AI-augmented intrusion and fraud as a present risk and re-baseline security budgets, incident playbooks, and vendor requirements accordingly.
Deep & Emerging TechNvidia adds a record $150bn to its share buyback
A $150B top-up — $235B total through FY 2028 — says Nvidia believes its own equity is a better use of cash than further accelerating capex or M&A. For operators, that’s a cue to plan on current GPU supply/demand dynamics persisting rather than expecting a sudden flood of cheaper capacity from new buildouts.
Deep & Emerging TechRed Queen Bio is using AI to design antibodies for future viruses, WSJ says
Red Queen Bio raising $36M to design antibodies for both natural and AI-enabled viruses shows biosecurity is now explicitly co-evolving with AI capabilities. Health and biotech operators should assume regulators will increasingly ask how your AI tools could both help and hurt — and whether you have countermeasures in the plan.